Antibiotic – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:47 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Antibiotic – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Moxifloxacin Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-moxifloxacin-market-2021-2025/ Tue, 08 Jun 2021 05:56:53 +0000 https://www.cri-report.com/?post_type=product&p=11760 In 2020, the sales value of Moxifloxacin fell by 41.23% in China, from CNY1.882 billion in 2019 to CNY1.106 billion in 2020.

The post Investigation Report on China’s Moxifloxacin Market 2021-2025 first appeared on CRI Report.

]]> Moxifloxacin is a fourth-generation synthetic quinolone antibacterial drug (8-methoxy-fluoroquinolone antibiotic) developed by Bayer Vital GmbH. It was approved for marketing by the FDA in December 1999. Moxifloxacin can be used to treat several infections, including respiratory infections, cellulitis, anthracnose, endocarditis, intra-abdominal infections, meningitis and tuberculosis. In 2002, Moxifloxacin tablets (400mg) were launched in China. In 2004, Moxifloxacin injection was launched for the treatment of adults suffering from upper and lower respiratory tract infections. In the first half of 2021, in addition to Bayer Vital GmbH, there are several manufacturer in the Moxifloxacin market in China, such as Nanjing Youke Pharmaceutical Co., Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Chengdu Zhengkang Pharmaceutical Co., Ltd. and Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd.

CRI’s survey data shows that the sales value of Moxifloxacin has grown steadily from 2016 to 2019 in China. In 2020, the sales value of Moxifloxacin fell by 41.23% in China, from CNY1.882 billion in 2019 to CNY1.106 billion in 2020. Due to the second batch of state-organized centralized procurement of medicines, and manufacturers of Moxifloxacin compete by reducing prices. Moxifloxacin of Bayer Vital GmbH dropped by 77.70%, and Moxifloxacin of Nanjing Youke Pharmaceutical Co., Ltd. dropped by 53.07%. The CAGR of the sales value of Moxifloxacin in 2016-2020 is -3.76% in China.

CRI predicts that with the effective relief of the COVID-19 epidemic, the sales of Moxifloxacin in the Chinese market will have a recovery growth in 2021-2025. In addition, there are 19 pharmaceutical companies that have entered the Chinese Moxifloxacin market by 2020. It is expected that the price of Moxifloxacin will decline with the addition of new manufacturers, and there is room for growth in sales volume and sales. At the same time, compared with similar drugs, Moxifloxacin has a broad antibacterial spectrum, strong curative effect and other advantages, so the sales volume of Moxifloxacin in China will maintain a growth trend.

Topics Covered:
-The impact of COVID-19 on China’s Moxifloxacin market
– Sales value of China’s Moxifloxacin 2016-2020
– Competitive landscape of China’s Moxifloxacin market
– Prices of Moxifloxacin in China
– Prices of Moxifloxacin in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Moxifloxacin market
– Prospect of China’s Moxifloxacin market from 2021 to 2025

The post Investigation Report on China’s Moxifloxacin Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Meropenem Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-meropenem-market-2021-2025/ Fri, 23 Apr 2021 13:03:00 +0000 https://www.cri-report.com/?post_type=product&p=11194 According to CRI's market research, the sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, the sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year.

The post Investigation Report on China’s Meropenem Market 2021-2025 first appeared on CRI Report.

]]> Meropenem is an antibiotic that is used to treat a variety of bacterial infections, including meningitis, pneumonia and so on. Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial Chemical Industries (ICI). It was launched in the Chinese market in 1999. Currently, besides Sumitomo Dainippon Pharma, the other main manufacturers in the Chinese market are Shenzhen Haibin Pharmaceutical, CSPC Ouyi Pharmaceutical Group, Hanhui Pharmaceuticals, and Haikou Pharmaceutical Factory.

According to CRI’s market research, the sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, the sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year. The main reason is that the COVID-19 epidemic has impacted the hospitals’ overall operation. The CAGR of sales value of Meropenem in China is 2% in 2016 to 2020.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Meropenem will have a recovery growth from 2021 to 2025. In addition, the strict limits on the usage of antibiotic drugs and the emergence of drug resistance have driven the demand for more effective antibacterial drugs. Therefore, Meropenem, as a new generation of antibacterial drugs, has the potential to expand its sales in the future.

Topics Covered:
-The impact of COVID-19 on China’s Meropenem market
– Sales value and volume of China’s Meropenem 2016-2020
– Competitive landscape of China’s Meropenem market
– Prices of Meropenem in China
– Prices of Meropenem in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Meropenem market
– Prospect of China’s Meropenem market from 2021 to 2025

The post Investigation Report on China’s Meropenem Market 2021-2025 first appeared on CRI Report.

]]>